Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
about
Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarineAdding pharmacogenomics to the development of new marine-derived anticancer agentsClear cell carcinoma of the ovary: molecular insights and future therapeutic perspectivesSignal Transducers and Activators of Transcription (STAT) Regulatory Networks in Marine Organisms: From Physiological Observations towards Marine Drug DiscoveryTrabectedin in soft tissue sarcomasImpact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.Mild hypoxia enhances proliferation and multipotency of human neural stem cellsRole of trabectedin in the treatment of soft tissue sarcomaClinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Development of distamycin-related DNA binding anticancer drugs.Preclinical and clinical results with the natural marine product ET-743.Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complexPM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity.Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).In-vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models.Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.Advances in the targeted therapy of liposarcoma.Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancerBRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patientsBioactive substances with anti-neoplastic efficacy from marine invertebrates: Bryozoa, Mollusca, Echinodermata and Urochordata.Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem CellsBRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinA Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignanciesDual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.Antimicrobial peptides from marine proteobacteria.Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin.Current treatment and clinical trials in ovarian cancer.Past, present and future of therapies in pediatric sarcomas.Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomasNew therapies in soft tissue sarcoma.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.Trabectedin: novel insights in the treatment of advanced sarcoma.
P2860
Q21284162-871CB032-C0FE-4251-86BC-AB7DB1F36445Q25254985-14E09D1C-C7BA-4C8A-B0CA-889BD0BC5C8BQ26749280-47B8CE42-CAF5-40E6-B842-E856E39E000BQ26799332-E10BD73B-CBF8-4BA3-9333-1AC153223E8FQ28085505-904178CB-4BE4-4CA6-9BEB-9F68ABE1A6FBQ33416931-E2BFF64B-3B5C-44DC-8722-74800EFE8C37Q33522237-6173E978-9988-47FD-BB89-99B80D60DCF9Q33916011-E7BB9AD7-CC55-4D01-98D6-BC78E4FF5E31Q33921802-3E8F460F-31CD-46A2-B2C9-EEDB7FEEADD3Q34481722-C53F6EC4-A8B8-4A39-B27D-0B58E6099D10Q34542908-CE9040C3-F437-4741-9D18-D7E90C9CD48DQ34580659-545D7B95-EFF0-4F84-B611-FD007EDC9433Q34581388-814ED4F4-AD25-4642-8DC8-D1362B426B09Q34594349-7DAD1859-CC82-496F-BD27-E846DE5BEA37Q34624706-C3BB6A30-F57F-432C-897E-40F91F4D38C1Q34650482-01701783-13C2-4E75-A9E5-82E8EBAC035FQ34688033-7AE4CD9B-C541-49CD-A52D-719A90D8A541Q34898364-C2151291-4340-40A7-9833-A511BBF62F85Q34952133-F1E28BAC-BBA1-4491-BE9A-64982A6DD432Q34996149-6EB72B57-77F8-4027-9443-295991DF6BFFQ35098302-C538C2BB-E18B-4804-916E-0E978FC57931Q35540360-5D3B2A7C-CF28-4D0A-90B6-97A99E5360BEQ35814987-AB96D92D-0E64-4B0A-B704-4D91771F2DFFQ36188973-CD6CFB6A-5965-4BB0-9040-FAE9B99A9E49Q36432104-F5C07B9B-DDC9-49F3-867D-06CA59AA0B8BQ36610752-4F6B60E2-B23D-4E78-A5D3-9F29ED9A3E92Q37005569-47325F77-902B-48A8-BBBA-6D845B2FD21CQ37163139-3198E47D-338C-413D-9BDE-55CBFE7F2280Q37295535-8D24EB96-D47E-4ABE-9147-884FACC4A3B1Q37303978-8A2268FC-8D3B-4AA0-B885-8625ADD0A5E1Q37383496-C4FEE950-7B6D-424F-B270-A03525288F83Q37724199-2F694770-2C2B-414C-8F9E-EDD7980F8EEBQ37725915-5067191C-F93C-4B00-A7B0-BC00963A644EQ37747771-B9B2D192-5A3A-4743-86E5-49CDD207C5C5Q37750812-460BC399-68E0-410D-9F53-73A410C645E8Q37760957-FC089077-71BD-4F03-97F3-0DC9EEBA95CEQ37854494-3DAB6C66-A761-4C38-BE67-499550D41AFBQ37969213-B71D1F2A-6AF5-46BF-9FB6-648FCACDB971Q38206366-989AE68A-D398-4B1D-AF78-28C6C02A36F4Q38206396-8F109B7B-F415-478F-98D0-6C159BC18DFA
P2860
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
@ast
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
@en
type
label
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
@ast
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
@en
prefLabel
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
@ast
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
@en
P2093
P1476
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
@en
P2093
P304
P356
10.1016/S0959-8049(00)00357-9
P577
2001-01-01T00:00:00Z